Media stories about Athenex (NASDAQ:ATNX) have been trending somewhat negative on Monday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athenex earned a news sentiment score of -0.05 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.9856942491272 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
NASDAQ:ATNX opened at $17.08 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.86 and a quick ratio of 1.49. The stock has a market capitalization of $1,084.45 and a price-to-earnings ratio of -7.36. Athenex has a 1-year low of $11.21 and a 1-year high of $20.79.
Athenex (NASDAQ:ATNX) last posted its quarterly earnings data on Monday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.33). The business had revenue of $14.87 million for the quarter. sell-side analysts expect that Athenex will post -1.4 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on ATNX. Zacks Investment Research raised shares of Athenex from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Thursday, March 29th. BidaskClub raised shares of Athenex from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 11th. Needham & Company LLC assumed coverage on shares of Athenex in a research report on Tuesday, March 6th. They issued a “buy” rating and a $30.00 price objective for the company. JPMorgan Chase upped their price objective on shares of Athenex from $22.20 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, January 24th. Finally, Deutsche Bank set a $20.00 price objective on shares of Athenex and gave the company a “buy” rating in a research report on Wednesday, January 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.86.
In related news, insider Jeffrey Yordon bought 5,000 shares of the business’s stock in a transaction dated Monday, March 26th. The shares were acquired at an average price of $14.69 per share, for a total transaction of $73,450.00. Following the purchase, the insider now owns 188,709 shares in the company, valued at approximately $2,772,135.21. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Rudolf Kwan bought 2,000 shares of the business’s stock in a transaction dated Monday, March 26th. The stock was bought at an average price of $14.65 per share, for a total transaction of $29,300.00. Following the purchase, the executive vice president now owns 82,224 shares in the company, valued at approximately $1,204,581.60. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 89,500 shares of company stock valued at $1,287,550.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/04/16/somewhat-critical-press-coverage-somewhat-unlikely-to-affect-athenex-atnx-stock-price.html.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.